Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | ITGAL | P20701 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 2/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803512 | 1.00 | HPGD (0.47) | HPGDL3MBTL1NPSR1RAD52ITGB2 | |
| SCHEMBL2906716 | 1.00 | HPGD (0.47) | HPGDL3MBTL1NPSR1RAD52ITGB2 | |
| SCHEMBL25937443 | 1.00 | HPGD (0.47) | HPGDL3MBTL1NPSR1RAD52ITGB2 | |
| SCHEMBL6341198 | 0.89 | HPGD (0.53) | HPGDL3MBTL1NPSR1RAD52ITGB2 | |
| SCHEMBL6341194 | 0.89 | HPGD (0.53) | HPGDL3MBTL1NPSR1RAD52ITGB2 | |
| SCHEMBL20205837 | 0.81 | ITGB2 (0.43) | L3MBTL1NPSR1ITGB2ICAM1ITGAL | |
| SCHEMBL20457145 | 0.81 | ITGB2 (0.43) | L3MBTL1NPSR1ITGB2ICAM1ITGAL | |
| SCHEMBL1266178 | 0.80 | RAD52 (0.46) | HPGDL3MBTL1NPSR1RAD52MEN1 | |
| SCHEMBL19368247 | 0.80 | RAD52 (0.46) | HPGDL3MBTL1NPSR1RAD52MEN1 | |
| SCHEMBL1266177 | 0.80 | RAD52 (0.46) | HPGDL3MBTL1NPSR1RAD52MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | claimed |
| EP-3962899-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | claimed |
| EP-4743453-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | Pretzel Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015178-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023144793-A1 | POL THETA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| EP-3962899-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HPGD 861/4885L3MBTL1 1558/4885NPSR1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.